Jane Wilcox, MD, MSc


Chief of the Section of Heart Failure Treatment
and Recovery Associate Professor of Medicine

University / Hospital Affiliation

Northwestern University Feinberg School of Medicine


Dr. Wilcox is the Chief of the Section of Heart Failure Treatment and Recovery, and an Associate Professor of Medicine at Northwestern University Feinberg School of Medicine. She is also the Associate Director of the T1 Center for Cardiovascular Therapeutics in the Bluhm Cardiovascular Institute. Dr. Wilcox is board certified in Advanced Heart Failure and Transplant. In addition to caring for patients with cardiomyopathy, advanced heart failure/transplant and mechanical assist devices (including durable LVADs and temporary support devices) on the inpatient service, Dr. Wilcox is the director of the Myocardial Recovery Clinic for patients with Heart Failure with recovered Ejection Fraction (HFrecEF). She also has expertise in muscular dystrophy associated cardiomyopathy and is an integral member of the multidisciplinary muscular dystrophy association (MDA) clinic at Northwestern. Dr. Wilcox’s research interests include characterization of the myocardial substrate among dilated cardiomyopathy (DCM) patients as it relates to myocardial recovery, novel cardiac imaging in DCM, early-phase trials of new therapeutics for genetic cardiomyopathies, and improving patient/caregiver self-management of ventricular assist devices.

Related Content

Manuscripts & Publications

Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction.

Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients

The purpose of this study was to examine prognostic value of T1- and T2-mapping techniques in heart transplant patients.

Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy

What is the prevalence of familial disease among patients with idiopathic dilated cardiomyopathy (DCM) and the lifetime risk of DCM for their first-degree family members by race and ethnicity?